Home MarketIpca Laboratories Ltd.

Ipca Laboratories Ltd. Stock Info: As on 2018-05-24 15:55:45

Nse

662.90

-4.45(-0.67%)
Change%
52 Week Range
400.00
11.00
760.00
30.00
Open666.15
Day's Range533.88 - 800.82
Value Traded (in ₹ Cr.) 1.81

Bse

662.80

-4.75(-0.71%)
Change %
52 Week Range
400.00
11.00
757.00
30.00
Open669.10
Day's Range534.04 - 801.06
Value Traded (in ₹ Cr.) 0.63

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 58,216,236.00 46.13%
Mutual Funds/UTI 27,094,350.00 21.47%
FII 19,999,449.00 15.85%
Employee 0.00 0.00%
Public 12,832,944.00 10.17%
Government 0.00 0.00%
Others 4,787,861.00 3.79%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 2.54
Basic EPS (Rs.) 14.92
Cash EPS 28.47
BVPerShare Excl 196.13
Operating Revenue 245.69
PBDITPerShare 35.86
Dividend 1.00
NPPerShare 14.92
Current Ratio 1.80
Quick Ratio 0.87
PriceToBV 3.18
Earnings 0.02
PBDIT Margin 14.59
PBT Margin 8.32
NP Margin 6.07
Return On Assets 4.74
Retention Ratios 0.00
Parameter Mar-17 (₹ Cr.) Yoy%change
Total Income 3,122.86
Total Expenses 2,864.66
EBITDA 452.54
PBT 258.20
PAT 188.29
Net Income 188.29
More
Parameter Sep-17 (₹ Cr.) 6M % change
Total Income 1,594.43
Total Expenses 1,494.09
EBITDA 12.95
PBT 88.37
PAT 76.22
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-17 (₹ Cr.) Yoy%change
Total share capital 25.24
Net worth 2,475.12
Investments 211.58
Total Liability 3,967.95
Total debt 529.04
Net block 2,040.84
Total Assets 3,967.95
Parameter Sep-17 (₹ Cr.) 6M % change
Total share capital 25.24
Net worth 2,247.78
Investments 142.42
Total Liability 3,862.28
Total debt 854.70
Net block 2,080.22
Total Assets 3,862.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

533.05 531.95 0.21
524.95580

Abbott India Ltd.

6671.7 6587.45 1.28
65106890

Ajanta Pharma Ltd.

977.6 987 -0.95
962.351074.5

Albert David Ltd.

362.35 362.75 -0.11
356.2383.15

Alembic Ltd.

48.85 50.8 -3.84
50.254

Alembic Pharmaceuticals Ltd.

420.7 422.3 -0.38
418.5491.2

Alkem Laboratories Ltd.

1957.55 1965.35 -0.4
18882036.65
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

47.5 49.05 -3.16
46.351.55

Aarti Drugs Ltd.

530 529.15 0.16
526585

Aayush Food & Herbs Ltd.

47.7 48.1 -0.83
4355

Abbott India Ltd.

6699.95 6593.7 1.61
6465.056872.5

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-17(in ₹ Cr.)
Cash from operating activities 265.65
Cash from investing activities -139.90
Cash from financing activities -156.39
Net change in cash -30.64

Stock Held By Mutual Fund Schemes

M Venkatesh appointed MRPL MD

M Venkatesh has been appointed as the Managing Director of Mangalore Refineries and Petrochemicals Limited (MRPL), an order issued by the Personnel Ministry said today. Vekatesh is at present Director (Refineries) in the MRPL, a subsidiary of the Oil and Natural Gas Corporation Limited (ONGC) He has been appointed to the post for a period of five years with effect from the date of his assumption of charge of the post on or after June 1, 2018, or till the date of his superannuation, the order said.

24-05-2018 11:42

TCS expands operations in Florida as part of Transamerica deal

India's largest IT services firm TCS today said it has expanded operations in Florida, US, with over 430 employees joining the company as part of its deal with Transamerica. In January, Tata Consultancy Services (TCS) had signed an over USD 2 billion deal with Transamerica to administer the latter's life insurance, annuity, supplemental health insurance, and workplace voluntary benefits products. It covered managing administration of more than 10 million policies. More than 430 former Transamerica employees now work for TCS at this new St Petersburg facility (in Florida) as part of recruiting and investing in more than 2,200 Transamerica jobs across the US in multiple locations, the Indian software services giant said in a statement. TCS will occupy several floors of Transamerica's building at 570 Carillon Parkway in St Petersburg, as part of a multi-year agreement with Transamerica... The St Petersburg office is a new US business centre for TCS, adding to the over 1,000 employees already serving American businesses throughout the state, it added. TCS said it has invested nearly USD 3 billion in the US over the past three years and has been among the top two IT services job creators in the country. TCS is a leading industry employer in the US, striving to help American companies like Transamerica to digitally transform their business and capitalise on rapidly evolving customer demands, TCS President and Global Head (Banking, Financial Services and Insurance Platforms) Suresh Muthuswami said. We look forward to partnering with St Petersburg's city, state and local organizations to further build upon our business and community impact, he added. The company said it has made tremendous community impact in Florida over past several years.

24-05-2018 11:16

Kotak India Growth Fund Series 4 - Direct Plan: change in investment factsheets for April

Kotak India Growth Fund Series 4 - Direct Plan has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.89 for Growth, while 52-Week High and Low ranges were Rs 10.35 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 - Direct Plan is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

Kotak India Growth Fund Series 4: change in investment factsheets for April

Kotak India Growth Fund Series 4 has announced change in investment factsheets and fund flash for the month ended April 30, 2018. As on Apr 30, 2018, the total size of the Fund was Rs 429.99 crores, compared with Rs 424.96 crores in the last month. The Fund's NAV per unit was Rs 9.88 for Growth, while 52-Week High and Low ranges were Rs 10.34 and Rs 9.51 respectively. The Equity - Diversified fund with Growth plan was launched on Jan 29, 2018 and managed by Fund Managers Harsha Upadhyaya, Devender Singhal. The top five companies based on a percentage of total holdings were ITC Ltd. (35.18 Cr.), HDFC Bank Ltd. (19.44 Cr.), Mahindra & Mahindra Ltd. (19.21 Cr.), Tata Motors Ltd. (17.02 Cr.) and Bata India Ltd. (16.05 Cr.). Kotak India Growth Fund Series 4 is promoted by Kotak Mahindra Mutual Fund and managed by Kotak Mahindra Asset Management Company Ltd..

24-05-2018 11:00

BLS International to assist Sopra Steria on UK visa renewals

Visa service provider BLS International today said theUnited Kingdom Visas and Immigration (UKVI) has awarded Sopra Steria a new contract to enable visa renewals for those individuals who are already in the UK. BLS International will support Sopra Steria and UKVI, a division of the UK Home Office responsible for deciding who can visit and stay within the UK, by establishing and delivering some of the key add value services under the contract, it said in a release. BLS International claims to handle about 12 million visa applications annually across the globe at present. Meanwhile, shares of the company were trading at Rs 172.55 apiece, up 1 per cent from the previous close at 10:50 hours on BSE.

24-05-2018 10:51

Ipca Laboratorie - Corporate Action-Board to consider Dividend

A meeting of the Board of Directors of the Company will be held on Tuesday, 29th May, 2018, inter-alia, to consider the Unaudited Financial Results for the 4th quarter and the Audited Financial Results for the financial year ended 31st March, 2018; recommendation of dividend for the said financial year; and Allotment of equity shares upon conversion of options granted under lpca Laboratories Ltd. - Employees Stock Option Scheme - 2014 (ESOS).

14-May-2018 10:33 AM

Ipca Laboratorie - A Meeting Of The Board Of Directors Of The Company Will Be Held On Tuesday, 29Th May, 2018

A meeting of the Board of Directors of the Company will be held on Tuesday, 29th May, 2018, inter-alia, to consider the Unaudited Financial Results for the 4th quarter and the Audited Financial Results for the financial year ended 31st March, 2018; recommendation of dividend for the said financial year; and Allotment of equity shares upon conversion of options granted under lpca Laboratories Ltd. - Employees Stock Option Scheme - 2014 (ESOS).

14-May-2018 10:30 AM

Ipca Laboratorie - Shareholding for the Period Ended March 31, 2018

Ipca Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018.

13-Apr-2018 06:49 PM

Ipca Laboratorie - Certificate Under Regulation 40(9) Of The Securities And Exchange Board Of India (Listing Obligations And

Pursuant to Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith a certified copy of the compliance certificate for the period ended March 31, 2018 under Regulation 40(9) issued by M/s. Parikh Parekh & Associates, practicing Company Secretaries.

11-Apr-2018 12:17 PM

Ipca Laboratorie - Compliance Certificate For The Half Year Ended March 31, 2018

Pursuant to the Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby confirm that activities in relation to both physical and electronic share transfer facility are maintained during the period October 1, 2017 to March 31, 2018 (both days inclusive) by the Company's Registrar and Share Transfer Agent, viz., Link Intime India Private Limited, which is registered as Registrar & Share Transfer Agent in Category-I with the Securities and Exchange Board of India vide Registration Number : INR000004058.

10-Apr-2018 06:03 PM

Ipca Laboratorie - Corporate Action-Board to consider Dividend

A meeting of the Board of Directors of the Company will be held on Tuesday, 29th May, 2018, inter-alia, to consider the Unaudited Financial Results for the 4th quarter and the Audited Financial Results for the financial year ended 31st March, 2018; recommendation of dividend for the said financial year; and Allotment of equity shares upon conversion of options granted under lpca Laboratories Ltd. - Employees Stock Option Scheme - 2014 (ESOS).

14-May-2018 10:33 AM

Ipca Laboratorie - A Meeting Of The Board Of Directors Of The Company Will Be Held On Tuesday, 29Th May, 2018

A meeting of the Board of Directors of the Company will be held on Tuesday, 29th May, 2018, inter-alia, to consider the Unaudited Financial Results for the 4th quarter and the Audited Financial Results for the financial year ended 31st March, 2018; recommendation of dividend for the said financial year; and Allotment of equity shares upon conversion of options granted under lpca Laboratories Ltd. - Employees Stock Option Scheme - 2014 (ESOS).

14-May-2018 10:30 AM

Ipca Laboratorie - Shareholding for the Period Ended March 31, 2018

Ipca Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2018.

13-Apr-2018 06:49 PM

Corporate Details

About Management

One of the first modern pharma factory of yesteryears was commissioned by Ipca at Mumbai in 1969. The company was originally promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine Association Limited.' in October 1949. The present management took over in November 1975 when the total turnover of the company was just Rs. 0.54 crores. Currently, this premise where Ipca started its operations, houses the Registered Office of the company. Key departments like International Marketing, R&D (Formulations) and Analytical Development Lab are located here. YEAR EVENTS 1949 - Ipca Laboratories Ltd. was incorporated on 19th October, in Mumbai, under the name `The Indian Pharmaceutical Combine Association Limited'. The Company manufacture pharmaceutical products such as tablets, capsules, vials and ampoules. The Company was promoted by a group of medical professionals viz., Dr. N.K. Chaina, Dr. A.M. Desai, Dr. N.S. Tibrawala, K.M. Shroff, S.F. Kirawal, U.H. Dalal and K.B. Mehla. 1964 - The name was subsequently changed to `Ipca Laboratories Ltd.' on 6th August 1964. The name was further changed to `Ipca Laboratories Private Limited' on 13th January 1966. The name of the company was again changed to `Ipca Laboratories Ltd.' on 9th August 1988. The company became a Public Limited Company on 24th March, 1993. 1975 - The management of the company was taken over by Amitabh Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C. Godha. 1994 - The Company undertook to set up a modern plant at Athal, Silvassa, for manufacture of pharmaceutical formulations. Plant and machinery comprising blenders, auto tablet coaters, fluid bed dryers, etc., procured indigenously. The Tatlam bulk drug unit capacity was increased to 500 TPA. 1995 - 9,225,000 No. of equity shares allotted to promoters, friends, relatives and associates (of these, 225,000 were Rights shares at a premium of Rs 120 per share). During February, the Company issued 3,275,000 No. of equity shares of Rs 10 each at a premium of Rs 120 per share of which 150,000 shares reserved for allotment on a preferential basis to employees of the Company (all were taken up). Balance 3,125,000 shares issued to the public (all were taken up). 2002-R S Hugar, former managing director of Global Trust Bank, has joined the board of directors of Ipca as non-executive chairman with effect from June 11, 2002. 2003 -Launched new domestic marketing division, ACTIVA , dedicated to Rheumatology Care. First Company in India to have such division for marketing superspeciality molecules. - Launched new domestic marketing division,Hy Care dedicated to Cardio-Diabetology segments. - Wholly owned subsidiary `Ipca Pharmaceuticals Inc.' incorporated in United States of America. -Wholly owned subsidiary `Ipca Laboratories (UK) Ltd.' incorporated in United Kingdom. - Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. 2004 -Members of the Company have approved the amalgamation in the nature of merger of Innotech Pharma Ltd., a 100% subsidiary of the Company, with Company -Ipca Laboratories Ltd. unveils novel injectable antibiotic combination of cefotaxime sodium with sulbactam sodium for the first time in the country under the brand name 'Sultax' -Received 'Lifetime Achievement Award' for the year2002-03 from from CHEMEXIL (Basic Chemicals,Pharmaceuticals & Cosmetics Export Promotion Council)for export promotion over the years. -Commissioned new formulation plant at Silvassa -Forbes Asia, a leading US business magazine selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia 2005 -Ipca Laboratories Ltd has informed that the Company has entered into a Joint Venture (JV) agreement with Chongqing Holley Holding Company Ltd of China. -Merger of Innotech Pharma Limited with Ipca Laboratories Limited in August, 2005. -Acquires Cardiac brand ISORDIL from Wyeth Limited. -Forbes Asia, a leading US business magazine selected Ipca, for the third consecutive year as one among the first 200 'Best under a Billion Company' in Asia. - Ipca Laboratories has given the Bonus in the Ratio of 1:1 2006 -Ipca Laboratories Enters into Strategic Alliance with Ranbaxy Pharmaceuticals Inc., for the US Market -Ipca Laboratories launches fixed dose ACT combination and stops manufacturing of single ingredient Oral Artemisinin derivatives. -Ipca's new plant at Dehradun commenced operation on 5th May, 2006 2007 -Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Atenolol Tablets -Ipca Laboratories granted US FDA approval for Hydroxychloroquine sulfate tablet -Ipca Laboratories - Acquisition of 100% shareholding of formulation dossier registration holding companies in Australia and N -Ipca launched eighth domestic marketing division, 'Altus' which caters to intensivists and surgeons. -Ipca has been awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. In the past, company has received same award for three consecutive years' 2003, 2004 and 2005. 2008 -Ipca Laboratories receives US FDA approval for Propranolol Hydrochloride Tablets -Tonira Pharma's Nandesari unit (API plant at Baroda) receives US-FDA approval. -Ipca Laboratories Ltd has re-appointed Mr. Premchand Godha as the Managing Director of the Company for a further period of 5 years w.e.f. April 01, 2008. -Ipca-Piparia, formulation manufacturing unit receives MHRA-UK approval. This is the 3rd plant after Athal and Kandla receiving this qualification. -WHO prequalify Ipca's dossier of ARTESUNATE + AMODIAQUINE Co Blister making Ipca the 2nd company in the world and the first Indian company to receive this prequalification. 2009 -Ipca received Best Patent Award during the year 2007 - 08 2010 - Ipca Laboratories Ltd has informed that the Board of Directors of the Company at its meeting held on January 21, 2010, inter alia, appointed Mr. Anand T Kusre as a Director of the Company. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2011 -Ipca Laboratories has received approval from UK Medicines and Healthcare Products Regulatory Agency for its fourth manufacturing unit at a Special Economic Zone in Indore for good manufacturing practices under the regulator. -Ipca labs bags nod to amalgamate Tonira Pharma 2012 -Mr. Dev Parkash Yadava has been appointed as an Additional Director of the Company -IPCA Laboratories bags USFDA nod Indore formulations manufacturing facility 2013 -IPCA received Corporate Citizen Award' for best corporate governance practice. -IPCA Dehradun won the "Energy Conservation" Award for the 3rd year in a row. -IPCA featured on the 8th position in the list of 'India's Most Admired Companies, in a survey carried out by Fortune India, in collaboration with The Hay Group, for the second time. -IPCA Laboratories said that SEZ Indore formulations manufacturing unit has been found acceptable after the inspection of US-FDA. 2014 -IPCA Laboratories "Acquisition of High Potency Oral Solid Dosage formulations manufacturing unit situated at Pithampur near Indore". -IPCA has entered into an alliance with Oncobiologics, Inc. USA for the development, manufacture and commercialization of biosimilar monoclonal antibody products. -IPCA Sports Club wins the E-Merck Inter-Pharma Cricket Tournament. -IPCA acquires formulations manufacturing unit located at Tarapur, Dist. Palghar, Maharashtra. -IPCA Sports Club wins Dreamz Trophy (T-20 & 40-overs format). -New product Launch - Pacimolr Active -Whistle Blower Policy implemented. 2016 -Ipca Lab wins Clinical and Research Excellence (CARE) awards. -Ipca was awarded by 'Indian Drug Manufacturers Association (IDMA) Best Formulation Patent (2014-15)' for its formulation patent of Hydroxychloroquine and its combinations in treatment of Diabetes Mellitus at 54th IDMA annual day celebration held on 23rd January 2016. -Ipca Laboratories wins the 'Clinical Trial result of the year' at the first annual CARE Award held at Boston, USA on 27th April 2016. -Ipca's Ratlam manufacturing Unit won 1st prize in National Energy Conservation Award 2016. This ceremony was hosted in Delhi on 14th December 2016. -Ipca Laboratories has been conferred with "Intellectual Property (IP) Excellence Award 2016" for adopting "The Best Practices in IP Intelligence" in a function organized in Mumbai on November 28th, 2016. 2017 - Ipca's Revelol Am NH2 Programme (National Healthy Heart Programme) has entered Limca Book of Records-December 2017. -Ipca's domestic marketing division, Intima launched brand Platigain. It is one more gem in the crown of Intima division. -Ipca Launched launch two new offsprings Pacimol MF tablets and Pacimol IV. - Ipca received `Fastest Growing Business Award 2017 during a Trade Meet of Renowned Liners with Exporters.

Registered Office

Village Ranu, (Taluka Padra),

2662-227300,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.